Introduction
The bcr-abl oncogene, produced from the t(9;22)(q34;q11) chromosomal translocations known as the Philadelphia chromosome (Ph), are associated with 95% of the cases of chronic myelogenous leukemia (CML), and also with 20% of the adult and 5% of the pediatric cases of acute lymphoblastic leukemia (ALL) (Faderl et al., 1999; Melo, 1996; Sawyers, 1999) . Depending on how much bcr sequence becomes fused to the abl sequence, dierent forms of Bcr-Abl proteins with dierent molecular weights are found in patients (Bcr-Abl/p185, Bcr-Abl/p210, and Bcr-Abl/p230). All forms of Bcr-Abl have a deregulated tyrosine-kinase activity and can activate multiple signal transduction pathways in cells (Raitano et al., 1997) . The most common form, Bcr-Abl/p210, is predominantly found in CML, while Bcr-Abl/p185 is predominantly found in Ph + ALL and Bcr-Abl/p230 is found in rare cases of a less aggressive form of CML (Faderl et al., 1999; Melo, 1996; Sawyers, 1999) .
To study the molecular mechanisms by which the bcr-abl oncogene acts in the pathogenesis of CML, extensive eorts have been made to establish laboratory animal models for CML. In earlier mouse models, Bcr-Abl often induced lymphoid and other nonmyeloproliferative hematological neoplasms (Daley et al., 1990; Elefanty and Cory, 1992; Elefanty et al., 1990; Heisterkamp et al., 1990; Honda et al., 1995; Kelliher et al., 1990; Voncken et al., 1995) . Recently, changes to improve expression of retrovirally transduced genes in early multipotential hematopoietic cells produced the conditions of a mouse CML model where Bcr-Abl/p210 rapidly induces a CML-like myeloproliferative disease in 100% of mice Pear et al., 1998; Zhang and Ren, 1998) . It was shown that the retroviral system used to infect bone marrow for this mouse CML model can target gene expression into multipotential hematopoietic cells, including cells that give long-term repopulation of multiple blood cell lineages (Pear et al., 1998; Zhang and Ren, 1998) . Furthermore, target cells infected with a bcr-abl retrovirus were reported to give rise to clonally-related cells of multiple hematopoietic lineages . As seen in the chronic phase of human CML, it is the myeloid lineage cells that are selectively expanded by Bcr-Abl/p210 in this mouse CML model.
It remains unclear why Bcr-Abl expression in stem and/or multipotential hematopoietic cells selectively induces the expansion of granulocytic cells. This could be due to speci®c intrinsic properties of the Bcr-Abl fusion protein, or it could be due to the properties of the target cells expressing the fusion protein. When cAbl activated by SH3 deletion and lacking any Bcr sequences (DSH3 c-Abl) was introduced into these same target cells, only lymphoid malignancies with an extended disease latency developed (Gross et al., 1999) . Therefore, the intrinsic properties of an abl oncogene can in¯uence whether myeloid cells are selectively expanded in vivo. However, DSH3 c-Abl also has a generally decreased oncogenic potential for in vitro transformation of cell lines as compared to Bcr-Abl (Gross et al., 1999) . This raises the question of whether it is a particular quantitative strength of oncogenic signals, or a speci®c combination of oncogenic signals uniquely provided by Bcr-Abl fusion proteins, that is required within the stem and/or multipotential hematopoietic cells for the selective and rapid myeloid cell expansion. To address this question we have compared the disease induced in an improved mouse CML model by Bcr-Abl and v-Abl.
Abelson murine leukemia virus (A-MuLV), originally found to cause pre-B cell leukemia/lymphoma when introduced into newborn mice by intraperitoneal or intravenous injection, was created by a recombination event that fused viral gag sequences to c-abl sequences, deleting the Abl SH3 domain in the process (Rosenberg and Witte, 1988) . Besides deletion of the Abl SH3 domain, the fusion of gag sequences to c-abl and accumulation of additional mutations within the SH3-deleted c-abl sequence also contribute to the strong oncogenic potential of v-Abl. v-Abl has been shown to activate multiple signal transduction pathways in cells, many of which are the same as those activated by Bcr-Abl (Raitano et al., 1997; Zou and Calame, 1999) . In earlier mouse CML models, where Bcr-Abl induced a variety of hematological diseases, there was a controversy as to whether v-Abl could directly induce myeloid cells to expand in vivo (Kelliher et al., 1990; Scott et al., 1991) . Later, Bcr-Abl and vAbl were shown to have the capacity to induce both lymphoid and myeloid colonies in vitro (Kelliher et al., 1993) . We can now make a direct comparison of the diseases induced by Bcr-Abl and v-Abl, because in our improved CML model Bcr-Abl consistently induces a rapid myeloproliferative disease, and the cells infected by the retrovirus are marked by expression of Green Fluorescent Protein (GFP). In this study we found that Bcr-Abl and v-Abl have distinct intrinsic properties in activating signaling pathways and in inducing hematological diseases. The model system described here will be useful to elucidate the molecular mechanisms underlying abl oncogene disease speci®city and myeloid versus lymphoid disease speci®city in general.
Results
Bcr-Abl selectively and rapidly expands myeloid cells in vivo, while v-Abl primarily induces the rapid in vivo expansion of B-lymphoblastic cells along with a minor population of myeloid cells
To compare directly the diseases induced by Bcr-Abl/ p210 and v-Abl/p160, these two abl oncogenes were introduced separately into mice using the conditions of an ecient mouse CML model, with both oncogenes expressed from the same Murine Stem Cell Virus (MSCV) retroviral vector (Pear et al., 1998; Zhang and Ren, 1998) . In this mouse CML model, titer-matched retroviruses are used to infect cells from a common pool of bone marrow (BM) that has been enriched in multipotential hematopoietic progenitors by 5-¯uor-ouracil (5-FU) treatment of donor mice. The infected 5-FU BM cells are introduced into irradiated recipient mice by bone marrow transplantation (BMT). In the ®rst experiment comparing Bcr-Abl and v-Abl, all BcrAbl/p210 BMT mice developed the typical CML-like myeloproliferative disease (Figures 1 and 2a) as previously described (Gross et al., 1999; Zhang and Ren, 1998) . As we commonly see with a high titer virus, the disease induced by Bcr-Abl/p210 is rapid and consistent among all mice, and is fatal within 3 weeks. By 14 days after BMT, the average peripheral white blood cell (WBC) count among the 5 Bcr-Abl/p210 BMT mice was 215 000/ml+41 000 (avg.+s.d.) ( Figure  1a ), seen on blood smears to be mostly granulocytes. Two of these mice died on day 15 after BMT, and because the remaining three mice were moribund they were sacri®ced and analysed (Figure 1b ). These mice displayed hepatomegaly (each of the three livers weighed 2.1 g), splenomegaly [spleen weight= 0.61 g+0.05 (avg.+s.d.), three samples measured], and pulmonary hemorrhages, the same general features previously described for the Bcr-Abl induced CML-like myeloproliferative disease (Pear et al., 1998; Zhang and Ren, 1998) . By comparison, a normal mouse liver weighs around 1 g and a normal mouse spleen weighs around 0.1 g. In addition, the elevated number of peripheral WBCs in these mice was shown by¯ow cytometry to be due to a massive expansion of myeloid (Mac-1 + ) cells, with large populations of both GFP + cells directly expanded by Bcr-Abl/p210 expression and GFP 7 bystander cells indirectly expanded (Figure 2a , Bcr-Abl/p210 BMT #8.18), as previously described (Zhang and Ren, 1998) .
The 10 v-Abl/p160 BMT mice clearly developed a dierent disease than Bcr-Abl/p210 BMT mice ( Figures  1 and 2) . First of all, the peripheral WBC counts did not increase as quickly as, and never reached levels as high as, was seen in the Bcr-Abl/p210 BMT mice ( Figure 1a ). Fourteen days after BMT, the average peripheral WBC count among the 10 v-Abl/p160 BMT mice was 41 000/ml+10 000 (avg.+s.d.), and the highest levels the peripheral WBC counts ever reached ranged from 94 000/ml to 174 000/ml (Figure 1a) . Secondly, the types of WBCs that expanded in v-Abl/ p160 BMT mice were dierent. As with the Bcr-Abl/ p210 BMT mice, many granulocytes could be seen in peripheral blood smears from the v-Abl/p160 BMT mice. However, many lymphoblast cells were also seen in the peripheral blood smears from v-Abl/p160 BMT mice. Flow cytometry analysis of the peripheral blood cells from the v-Abl/p160 mice 17 days after BMT showed that most of the GFP + cells were B lineage cells (B220 (Hardy et al., 1991) . As the disease progressed following day 17 after BMT, the total peripheral WBC counts increased only marginally, or in some mice actually decreased (Figure 1a ). During this same time, the proportion of GFP + B-lymphoblastic cells in the peripheral blood decreased (Figure 2a , compare v-Abl/ p160 BMT #8.10 peripheral blood day 17 and day 22). This decrease of lymphoblastic cells in peripheral blood correlates with the occurrence of bloody pleural eusion (described below). A large proportion of GFP + B-lymphoblastic cells was still found in the spleen, bone marrow, and pleural eusion of v-Abl/ p160 BMT mice. Four v-Abl/p160 BMT mice died on day 22 after BMT, at the same time four other mice became moribund and were sacri®ced and analysed, while the remaining two mice died by day 26 after BMT ( Figure 1b) . Pleural eusion was found in nine of the 10 v-Abl/p160 BMT mice, and is a likely cause of death. Pleural eusion was seen as 0.5 ± 1 ml of unclotted, bloody¯uid ®lling the chest cavity, containing red blood cells and a high concentration of GFP + lymphoblastic cells (Figure 2a , v-Abl/p160 BMT #8.10 pleural eusion). Splenomegaly was present [spleen weight=0.59 g+0.10 (avg.+s.d.) , six samples measured], but unlike the Bcr-Abl/p210 BMT mice a pronounced hepatomegaly was not seen [liver weight=1.14 g+0.17 (avg.+s.d.) , six samples measured]. Together, these results show that even when introduced into mice using the conditions under which Bcr-Abl exclusively induces a CML-like myeloproliferative disorder, v-Abl/p160 primarily induces a rapid B-lymphoblastic disease, and directly expands only a minor population of myeloid cells. As in the CML-like myeloproliferative disease induced by Bcr-Abl/p210, the B-lymphoblastic disease induced by v-Abl/p160 was also characterized by the indirect expansion of a large population of bystander (GFP 7 ) myeloid cells.
Bcr-Abl induces more myeloid colonies and greater myeloid cell proliferation than v-Abl in vitro
The dierence seen between Bcr-Abl/p210 and v-Abl/ p160 in the direct in vivo expansion of myeloid cells could be due to two main factors. Bcr-Abl/p210 may have more ability than v-Abl/p160 to induce the expansion of myeloid cells. Alternatively, Bcr-Abl/ p210 and v-Abl/p160 may have the same ability to induce the expansion of myeloid cells, but v-Abl may (Table 1 and Figure 3 ). We found that Bcr-Abl/p210 consistently induced the growth of more colonies than v-Abl/p160 (Table 1) . Furthermore, the Bcr-Abl/p210-induced colonies are larger and occur with three main types of morphology ( Figure 3a) . In contrast, the v-Abl/p160-induced colonies are smaller with a more sparse and loose morphology ( Figure 3a) . The morphologies of these colonies are typical of the colonies formed by myeloid lineage cells in vitro. To characterize the types of cells in these colonies, we examined cytospin preparations made from several colonies of each type, after 7 days and 14 days of growth in soft agar (Figure 3b ). Microscopic examination con®rmed that Bcr-Abl/p210 and v-Abl/p160 colonies were composed of myeloid cells (primarily granulocytes and/or macrophages) ( Figure 3b ). Among the colonies examined the identity of only one v-Abl/p160 colony could not be determined. However, it is clear that under the conditions used in these experiments the vast majority of colonies that grew were composed of myeloid lineage cells, and the growth of lymphoid colonies was either rare or did not occur, possibly because the 5-FU BM is highly enriched for early multipotential hematopoietic cells and SCF, IL-3 and IL-6 are present during the 2-day infection procedure.
This in vitro result suggests that one reason v-Abl/ p160 directly expanded a smaller population of myeloid cells than Bcr-Abl/p210 in vivo is because Bcr-Abl/p210 does indeed have a greater intrinsic capacity to induce cytokine-independent myeloid cell growth. It is especially interesting to note that the large colonies induced by Bcr-Abl/p210 (Figure 3, ®rst 1545 (1530 ± 1560) 0.08 (0.06 ± 0.1) 6 (5 ± 7) 2 (2 ± 3) 6.1 (5.5 ± 6.7) 12 bcr-abl/p210 n=2 71350 (67100 ± 75600) 0.44 (0.38 ± 0.49) 57 (55 ± 58) 37 (35 ± 37) 7.0 (5.0 ± 9.0) v-abl/p160 n=3 7440 (5240 ± 8820) 0.22 (0.16 ± 0.25) 21 (18 ± 24) 11 (6 ± 15) 9.2 (7.5 ± 11.5) gfp vector n=2 4690 (4230 ± 5150) 0.13 (0.12 ± 0.13) 7 (6 ± 7) 1 (1 ± 2) 10.8 (8.5 ± 13.0) 15 bcr-abl/p210 n=2 235 000 (205 000 ± 264 000) 0.68 (0.61 ± 0.74) 60 (54 ± 65) 26 (17 ± 34) 4.8 (4.5 ± 5.0) v-abl/p160 n=3 33 000 (29 000 ± 40 000) 0.29 (0.26 ± 0.33) 24 (22 ± 27) 6 (4 ± 9) 13.0 (11.0 ± 15.5) gfp vector n=2 21 000 (15 000 ± 26 000) 0.13 (both 0.13) 7 (6 ± 7) The expression of GFP and lineage markers was determined bȳ ow cytometry. Figure 4 Immunophenotype analysis of spleen cells from Bcr-Abl/p210, v-Abl/p160, and GFP vector BMT mice over the ®rst 3 weeks following BMT. (a) Representative¯ow cytometric analyses of spleen cells from Bcr-Abl/p210, v-Abl/p160, and GFP vector BMT mice at 9, 12, 15 and 19 days after BMT are shown. Spleen cells stained with the indicated antibodies were analysed for expression of cell surface markers and GFP. Since between 9 and 19 days after BMT very few GFP + cells with lineage markers other than Mac-1 and B220 were present in Bcr-Abl/p210, v-Abl/p160, and GFP vector BMT mice, only representative results of the Mac-1 and B220 staining are shown. The peripheral WBC counts and spleen weight for each mouse at the indicated time are shown. (b) Spleen cells from Bcr-Abl/p210 and v-Abl/p160 BMT mice at an early stage of disease development (as judged by the time after BMT, the degree of splenomegaly, and the peripheral WBC counts) and a GFP vector BMT mouse were stained with a mixture of seven phycoerytherin-conjugated antibodies against lineage markers (Mac-1, Gr-1, B220, CD3, CD4, CD8, Ter-119) and column), which represent cells that are induced by BcrAbl/p210 to undergo extensive cytokine-independent proliferation, had more immature myeloid cells after 7 days of growth in soft agar. In contrast, the small, sparse colonies with much less cell proliferation induced by Bcr-Abl/p210 ( To determine more precisely how the dierent disease phenotypes induced by Bcr-Abl/p210 and vAbl/p160 arise, we compared the eects of Bcr-Abl/ p210 and v-Abl/p160 at earlier time points following BMT. Titer-matched retroviruses were used under the conditions of our mouse CML model to introduce MSCV-bcr-abl/p210-IRES-gfp, MSCV-v-abl/p160-IRES-gfp, or MSCV-IRES-gfp vectors into mice. At 9, 12, 15 and 19 days after BMT, mice from each group were chosen randomly for further analysis: two Bcr-Abl/ p210 BMT mice, three v-Abl/p160 BMT mice, and two GFP vector BMT mice at each time point, except on day 19 where only one Bcr-Abl/p210 mouse remained to be analysed along with the mice from the other groups ( Figure 4a and Table 2 ). At each time point, spleen and bone marrow cells from each mouse were analysed for expression of GFP and the lineage markers Mac-1, B220, and Thy-1.2, and cells from one mouse from each group were also checked for expression of the lineage marker Ter-119. The only major populations of GFP + /lineage marker + cells seen within 19 days after BMT were Mac-1 + or B220 + . On day 9 after BMT, the peripheral WBC counts were still low among all three groups of mice and the Bcr-Abl/p210 BMT mice showed only a small increase in spleen size (Table 2) . However, Bcr-Abl/p210 and vAbl/p160 BMT mice had many more GFP + cells in spleen and bone marrow than the GFP vector BMT mice ( Figure 4a and Table 2 ), indicating that hematopoietic cells targeted by Bcr-Abl/p210 and vAbl/p160 had already undergone expansion. Among these expanded GFP + cells, the majority in both BcrAbl/p210 and v-Abl/p160 BMT mice were GFP + /Mac-1 7 /B220 7 cells (Figure 4a and Table 2 ). As shown below, these GFP + /Mac-1 7 /B220 7 cells are Lin 7 early immature hematopoietic cells (Figure 4b and c) . Some GFP + /Mac-1 + cells were also present in these mice 9 days after BMT, whereas very few GFP + /B220
+ cells were present at this stage (Figure 4a) .
Interestingly, it was in later time points examined that Bcr-Abl/p210 and v-Abl/p160 demonstrated distinct oncogenic potentials in expansion of myeloid versus lymphoid lineages. By day 12 the peripheral WBC counts and spleen weight had dramatically increased in Bcr-Abl/p210 BMT mice ( Table 2) Table 2 , and data not shown). In contrast, the peripheral WBC counts and spleen weight in v-Abl/ p160 BMT mice increased more slowly ( Table 2) 
/B220
7 cells observed in the previous series of experiments to be expanded early in the course of disease development ( Figure 4a and Table 2 ) are early immature hematopoietic cells.
The lack of IL-7Ra expression on the GFP + /Lin 7 cells expanded by both Bcr-Abl/p210 and v-Abl/p160 suggests that neither of these oncogenes induces the accumulation of a population of cells at the level of the previously described common lymphoid progenitor (Kondo et al., 1997) . However, there could be a number of hematopoietic cell types within the GFP + / Lin 7 cells with bi-modal expression of c-kit seen to be expanded in the Bcr-Abl/p210 and v-Abl/p160 mice (Figure 4b ), including both myeloid progenitors and multipotential hematopoietic progenitor cells (Akashi et al., 2000; Allman et al., 1999; Kondo et al., 1997) . It is notable that v-Abl/p160 mice at a later time point had dierent GFP + /Lin 7 populations than in the earlier stage of disease development (Figure 4b (Figure 4c , left side). These dierences may represent dierent stages of disease development in dierent mice.
We also found that the total number of bone marrow cells recovered from Bcr-Abl/p210, v-Abl/ p160, and GFP vector BMT mice diered at later time points after BMT (Table 2) . Early after BMT, all three groups of mice had a relatively low number of cells in their BM (Table 2 ). The GFP vector BMT mice had steadily increasing numbers of BM cells over time, and the number of BM cells also increased in v-Abl/p160 BMT mice (Table 2) .
However, the total number of BM cells in BcrAbl/p210 BMT mice remained low, while the number of spleen cells in Bcr-Abl/p210 BMT mice was massively expanded (Table 2 and Figure 4) . The lower number of bone marrow cells in Bcr-Abl/p210 BMT mice may re¯ect the increased maturation of myeloid cells, premature release of Bcr-Abl-cells, as well as massive extramedullary hematopoiesis in spleen and liver ± hallmarks of human CML (Verfaillie et al., 1997a,b) .
Bcr-Abl induces greater STAT5 activation than v-Abl
In searching for the molecular basis of the dierent leukemogenic potentials of Bcr-Abl and v-Abl, the protein expression level of the two oncoproteins in this mouse CML model and the total tyrosine-phosphorylation pro®les of cells from Bcr-Abl/p210 and v-Abl/ p160 BMT mice were measured by immunoblotting lysates from equal numbers of peripheral blood WBCs from diseased mice (Figure 5a ). Lysate from the K562 cell line, which expresses a high level of Bcr-Abl/p210 protein, was included as a positive control, and lysate from spleen cells of a GFP vector BMT mouse was included as a negative control (Figure 5a) (Figure 2a and data not shown). The anti-Abl immunoblot shows that both vAbl/p160 and Bcr-Abl/p210 proteins were expressed in this mouse CML model (Figure 5a, top panel) . Total tyrosine-phosphorylation pro®les showed a similar overall amount of tyrosine-phosphorylated proteins in cells from Bcr-Abl/p210 and v-Abl/p160 BMT mice, with most major bands in common (Figure 5a , lower panel). Bcr-Abl/p210 BMT lysates had a more prominent tyrosine-phosphorylated band around 39 kDa, which may be Crk/Crkl. v-Abl/p160 BMT lysates had a much more prominent tyrosine-phosphorylated band around 60 ± 70 kDa, and either greater tyrosine-phosphorylation or additional bands around 120 kDa (Figure 5a, lower panel) . It should be noted that any dierence in tyrosine-phosphorylation pro®les could be due to expression of v-Abl/p160 and Bcr-Abl/p210 in dierent types of cell populations.
To solve this problem we need to compare directly the relative ability of Bcr-Abl/p210 and v-Abl/p160 to induce the activation of important signaling pathways in a single cell type, as a common cellular context. In one of the single cell types we studied, NIH3T3, we found that Bcr-Abl/p210 and v-Abl/p160 have distinct intrinsic potentials to activate STAT5 (Figures 5b,c) . In this study, NIH3T3 cells were infected with titermatched MSCV-bcr-abl/p210-IRES-gfp, MSCV-v-abl/ p160-IRES-gfp, and MSCV-IRES-gfp retroviruses, then 3 days after infection lysates were made from infected cells that had been maintained in standard media or had been starved for 24 h. To detect the activation status of signaling pathways, we used antibodies that recognize activation-speci®c phosphorylated sites of the signaling proteins Erk 1 and 2, Akt, STAT3, and STAT5A and B (see Materials and methods), because these proteins represent pathways that have previously been shown to be activated by Abl oncoproteins (Akt and STATs), and a major pathway downstream of Ras (Erk) (reviewed in Raitano et al. (1997); Zou and Calame (1999) ).
While there was little or no dierence seen in the amount of activated Akt or Erk present in cells that expressed either Bcr-Abl/p210 or v-Abl/p160, greater activation of STAT3 was seen in cells that expressed vAbl/p160 versus Bcr-Abl/p210, and greater activation of STAT5 was seen in cells that expressed Bcr-Abl/ p210 versus v-Abl/p160 (Figure 5b ). To test if the large dierence in STAT3 or STAT5 activation with BcrAbl/p210 versus v-Abl/p160 occurred only with shortterm expression of the oncoproteins during transient infection, we examined the activation of the signaling pathways in NIH3T3 cell lines transformed by either Bcr-Abl/p210 or v-Abl/p160 (Figure 5c ). Even in transformed NIH3T3 cell lines, the cells transformed by Bcr-Abl/p210 contained much more activated STAT5 than the v-Abl/p160 transformed NIH3T3 lines (Figure 5c ). However, the amount of activated STAT3 was similar in all the transformed NIH3T3 lines (Figure 5c ). Therefore, within a single type of cell, maintained under equal conditions, Bcr-Abl/p210 did induce much greater constitutive activation of STAT5 than v-Abl/p160 in both transient infection of cells and in transformed NIH3T3 lines. The consistent dierence in the activation of STAT5 by Bcr-Abl/p210 and vAbl/p160 suggests that STAT5 activation might be one of the important factors in the induction of neoplastic myeloid cell growth by Abl oncoproteins.
Discussion
We used the conditions of an ecient mouse CML model to compare the ability of Bcr-Ab/p210 and vAbl/p160 to induce the neoplastic expansion of myeloid cells in vivo. Early in the course of disease, both Bcr-Abl/p210 and v-Abl/p160 were seen to expand early immature hematopoietic cells, and then exhibited their unique oncogenic properties in lineage marker + cells. Under conditions where Bcr-Abl/p210 induced a CML-like myeloproliferative disease in 100% of mice, v-Abl/p160 primarily induced the rapid expansion of B-lymphoblastic cells in vivo, and directly expanded only a minor population of myeloid cells. As previously described for the CML-like disease induced by Bcr-Abl/p210 (Zhang and Ren, 1998), the Blymphoblastic disease induced by v-Abl/p160 was accompanied by the indirect expansion of a population of uninfected, bystander myeloid cells. In vitro, 5-FU BM infected by Bcr-Abl/p210 formed many more colonies in soft agar, with much greater proliferation in most colonies, than v-Abl/p160-infected bone marrow. Together, these results indicate that Bcr-Abl/ p210 has a greater intrinsic capacity than v-Abl/p160 to induce neoplastic myeloid cell growth. We also found that when the Abl oncoproteins were transiently expressed in NIH3T3 cells, and also in NIH3T3 lines transformed by Bcr-Abl/p210 or v-Abl/p160, expression of Bcr-Abl/p210 resulted in much more activated STAT5 than in cells that expressed v-Abl/p160. This correlation suggests that activation of STAT5 might be one of the important factors in the induction of neoplastic myeloid cell growth by Abl oncoproteins, and may therefore be a part of the mechanism of abl oncogene disease speci®city. Lysates from equal numbers of cells, and 10 mg of lysate from K562 cells, were run on 6 ± 15% polyacrylamide gradient gels, transferred to nitrocellulose ®lters, and probed with anti-Abl and antiphosphotyrosine antibodies, as indicated. (b) Total cell lysates were made from NIH3T3 cells 3 days following infection with the indicated titer-matched viruses, then equal amounts of each lysate and lysate from the K562 cell line were run on a 6 ± 15% polyacrylamide gradient gel and transferred to a nitrocellulose ®lter. Filters were probed ®rst with a phospho-speci®c antibody, then stripped and reprobed with the corresponding non-phosphospeci®c antibody, as indicated. Identical blots were probed in parallel, so each blot was only stripped and re-probed one time. Anti-actin was used as a loading control. (c) Total cell lysates were made from NIH3T3 cell lines transformed by either BcrAbl/p210 or v-Abl/p160, then equal amounts of each lysate and lysate from the K562 cell line were run on a 6 ± 15% polyacrylamide gradient gel, transferred to nitrocellulose ®lters, and probed as in (b) It was previously shown that Bcr-Abl/p210 and vAbl/p160 stimulated both myeloid and lymphoid colony formation in vitro from 5-FU BM, and that v-Abl/p160 induced more myeloid colonies than BcrAbl/p210 (Kelliher et al., 1993) . However, under the conditions of the earlier experiment Bcr-Abl/p210 ineciently induced a CML-like myeloproliferative disease and often induced lymphoid and other hematological neoplasms (Kelliher et al., 1990 ). In the model system used in this study Bcr-Abl/p210 eciently and exclusively induces a CML-like myeloproliferative disease in vivo. Under our bone marrow transduction condition, Bcr-Abl/p210 and v-Abl/p160 induced only myeloid colonies in vitro, and Bcr-Abl/ p210 had a greater ability than v-Abl/p160 to stimulate myeloid cell growth in vitro (Table 1 and Figure 3) . The dierence in the results of the current and previous studies might be due to targeting dierent types of hematopoietic cells by the dierent experimental systems used. The dierences between these systems include dierent cytokines (IL-3 vs. IL-3+ IL-6+SCF), dierent vectors and retroviral transduction protocols, and dierent dosages of 5-FU used to treat donor mice. Our results demonstrated that in cells that are relevant to development of a CML-like disease, Bcr-Abl/p210 has a greater intrinsic potential to stimulate myeloid cell growth than v-Abl/p160 both in vivo and in vitro.
In this study we did not detect the other hematological neoplasms in v-Abl/p160 BMT mice, such as mastocytosis, that have been reported in earlier studies (Gurish et al., 1995) . In addition, the disease latency in v-Abl/p160 BMT mice was shorter in this study than in previous studies, which is consistent with the ecient targeting of early multipotential hematopoietic cells under the conditions used in this study. Once again, the dierence in the results of the current and previous studies might be due to targeting dierent types of hematopoietic cells by the dierent experimental systems used.
All three forms of Bcr-Abl (Bcr-Abl/p185, Bcr-Abl/ p210, and Bcr-Abl/p230) have been shown to induce an equivalent myeloproliferative disease similar to the chronic phase of CML in this improved mouse CML model Zhang and Ren, unpublished) . Yet under the same condition v-Abl/p160 primarily induced the rapid neoplastic expansion of immature Blymphoblastic cells, even though both Bcr-Abl/p210 and v-Abl/p160 were shown to expand early immature hematopoietic cells. It is possible that Bcr-Abl and vAbl could aect the dierentiation of the same multipotential progenitors prior to lineage commitment, or the oncogenes could aect the selection of myeloid versus lymphoid lineages after lineage commitment. In either case, the presence of a small population of GFP + /Mac-1 + cells in the v-Abl/p160 BMT mice and the decreased growth and proliferation in vitro of myeloid colonies from v-Abl/p160-infected BM suggest that v-Abl/p160 does have less oncogenic potential to expand committed myeloid cells. Therefore, at least one factor that determines the myeloid versus lymphoid disease speci®city of abl oncogenes is the potential for expansion of committed myeloid cells.
Bcr-Abl/p210 was shown to expand both infected GFP + and uninfected GFP 7 myeloid cells, indicating that Bcr-Abl/p210 stimulates production of growth promoting cytokines (Zhang and Ren, 1998) . Indeed, it was found that Bcr-Abl/p210 induced excess production of IL-3 and GM-CSF (Zhang and Ren, 1998) . In this study we found that v-Abl/p160 also induced the expansion of GFP 7 myeloid cells, suggesting that the dierent disease phenotypes induced by Bcr-Abl/p210 and v-Abl/p160 are not due to the lack of ability of vAbl/p160 to stimulate the production of cytokines that promote myeloid cell growth.
Constitutively activated STAT5 has been reported in cells transformed by either Bcr-Abl/p210 or v-Abl/p160 (Carlesso et al., 1996; Chai et al., 1997; Danial et al., 1995; Ilaria and Van Etten, 1996; Shuai et al., 1996) . However, our study provides a direct comparison in the same cellular context of the relative ability of BcrAbl/p210 versus v-Abl/p160 to activate STAT5. It has been suggested that Bcr-Abl and v-Abl activate STAT proteins through dierent mechanisms, either, respectively, independent of or dependent on activation of Jak proteins (Danial et al., 1998) . The dierent abilities we observed of these two oncogenes to activate STAT5 within the same cellular context, NIH3T3 cells, may re¯ect the use of dierent mechanisms to activate STAT5. Since the relative ability of Bcr-Abl/p210 and v-Abl/p160 to activate STAT5 correlates with their in vivo potential for directly expanding myeloid cells, the relative degree of STAT5 activation by these abl oncogenes may contribute to their dierent myeloid expansion potentials. Interestingly, it has recently been shown that STAT5 does play a critical role in myelopoiesis and erythropoiesis in non-steady state conditions, such as during the rapid expansion of cells under stress/pathological conditions or during embryonic development (Kieslinger et al., 2000; Socolovsky et al., 1999) .
In our model system, v-Abl/p160 did not simply show a decreased oncogenic potential for myeloid cells, but it also rapidly induced an acute B-lymphoblastic leukemia/lymphoma. This is especially interesting because Bcr-Abl/p185, which is predominantly found in Ph + ALL, induces only a CML-like disease in this mouse CML model Zhang and Ren, unpublished) . Although it is not clear how v-Abl/p160-induced ALL is relevant to Ph + ALL, further studies of the dierent intrinsic properties of Bcr-Abl/p210 and v-Abl/p160 will help to understand the general mechanisms underlying the development of myeloid versus lymphoid neoplasms.
Materials and methods

DNA constructs
To create MSCV-v-abl/p160-IRES-gfp the vector pGD-v-abl (Scott et al., 1991) was digested with PvuI, the PvuI ends were blunted with T4 DNA polymerase, then the DNA was digested with DraI and ligated into the HpaI site of MSCV-IRES-gfp (Zhang and Ren, 1998) . MSCV-bcr-abl/p210-IRESgfp was described previously (Zhang and Ren, 1998) .
Retroviruses, bone marrow infection and transplantation, and in vitro soft agar colony assays Retroviral vectors were packaged as described (Pear et al., 1993) , and viral supernatants were collected and held at 48C, while samples of each virus were titered as previously described (Gross et al., 1999) . Viruses were normalized to give equivalent titers and used to infect bone marrow cells for the mouse CML model and cultured cells for in vitro studies. As described (Pear et al., 1998; Zhang and Ren, 1998) , bone marrow cells from 5-¯uorouracil (5 mg/mouse) treated male donor BALB/cByJ mice (5-FU BM) (The Jackson Laboratory, Bar Harbor, ME, USA) were infected for 2 days. Bone marrow transplantation (BMT) of these infected cells was performed by injecting 4610 5 BM cells into the tail vein of each of the lethally irradiated (26450 rads, 4 h between each dose) female recipient BALB/cByJ mice.
In vitro soft agar bone marrow colony assays were performed as described (Rosenberg and Baltimore, 1976) , with modi®cations. Infected 5-FU BM cells were plated in DMEM with 20% FBS, antibiotics, 50 mM 2-mercaptoethanol, and 0.3% bacto-agar, on a layer of media with 0.6% bacto-agar. Colonies were counted after 10 days.
Bone marrow colonies were characterized by the colony morphology, and by examining cytospin preparations of the cells from individual colonies after 7 or 14 days of growth. Cytospin preparations were made by removing a single colony from the soft agar with a pasteur pipet into 100 ml of FBS, suspending the cells from the colony with a micropipettor, cytospinning the 100 ml of cells onto a micrscope slide, and staining the cells with the Hema 3 Stain Set (Fisher Scienti®c, Pittsburgh, PA, USA).
Transformation of cell lines in vitro
NIH3T3 cells were infected with either MSCV-bcr-abl/p210-IRES-gfp or MSCV-v-abl/p160-IRES-gfp viruses and plated in soft agar. Anchorage-independent colonies were removed and transformed lines that survived and expanded were characterized for GFP expression by¯ow cytometry and Abl oncoprotein expression by Western blotting.
Analysis of disease phenotype in mice
Initially, beginning 2 weeks after BMT, mice were monitored with peripheral blood white blood cell (WBC) counts, and blood smears stained with the Hema 3 Stain Set (Fisher Scienti®c). When peripheral WBC counts became elevated, immunophenotype and GFP expression were measured bȳ ow cytometry. After death or sacri®ce due to moribund condition, the mice were examined for tumors or internal abnormalities, and samples of tumors and tissues were removed for analysis. For analysis of mice over the course of disease development, randomly chosen mice from the BcrAbl/p210 and v-Abl/p160 BMT groups and from the GFP vector BMT group were analysed at 9, 12, 15, and 19 days after BMT. For analysis of lineage marker negative cells early in disease development or cell repopulation, Bcr-Abl/p210, vAbl/p160, and GFP vector mice were analysed 15 days after BMT. For analysis of lineage marker negative cells at a late stage in the v-Abl/p160 induced disease, v-Abl/p160 mice were analysed 22 days after BMT.
Flow cytometry
Standard protocols for antibody staining of cell surface proteins were followed (Coligan et al., 1996) . The following antibody reagents were used (all from Pharmingen; antibody clone numbers are given in parentheses): phycoerytherinconjugated Mac-1 (M1/70), Gr-1 (RB6-8C5), B220 (RA3-6B2), CD3e (145-2C11), CD4 (H129.19), CD8a (53-6.7), Ter-119, Thy-1.2 (53-2.1), Heat Stable Antigen (M1/69); biotinconjugated CD43 (S7), BP-1 (6C3/BP-1 ag), IgM (R6-60.2), IL7-Ra (B12-1), c-kit (2B8); streptavidin-allophycocyanin. Flow cytometry measurements were made on a FACSCalibur machine and data analysed with CellQuest software (Becton Dickinson, San Jose, CA, USA).
Cell lysates and immunoblotting
Total cell lysates of samples from mice were prepared as described (Gross et al., 1999) , and equal volumes of these lysates were run on 6 ± 15% polyacrylamide gradient gels. Total cell lysates from NIH3T3 cells were prepared as described (Gross et al., 1999) , and equal amounts of total protein of each lysate were run on 6 ± 15% polyacrylamide gradient gels.
Protein blots were probed with: anti-Abl (Ab-3, Oncogene Research Products, Cambridge, MA, USA); anti-phosphotyrosine (clone PY20); anti-actin (clone AC-40, Sigma, St. Louis, MO, USA); anti-phospho-STAT5A/B (Y694/Y699) (clone 8-5-2, Upstate Biotechnology, Lake Placid, NY, USA); anti-STAT5 (clone 89, Transduction Laboratories, Lexington, KY, USA); anti-phospho-STAT3 (Y705), anti-STAT3, antiphospho-Akt (Ser473), anti-Akt, anti-phospho-p44/42 (Thr202/Tyr204) MAP kinases (Erk1 and Erk2), anti-p44/42 MAP kinases (Erk1 and Erk2) (New England Biolabs, Beverly, MA, USA). Secondary antibodies were HRP-labeled goat anti-mouse IgG or goat anti-rabbit IgG (Southern Biotechnology Associates, Inc., Birmingham, AL, USA).
